Compare CENT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | NVCR |
|---|---|---|
| Founded | 1955 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 1996 | 2015 |
| Metric | CENT | NVCR |
|---|---|---|
| Price | $45.01 | $14.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $53.00 | $26.86 |
| AVG Volume (30 Days) | 66.2K | ★ 1.4M |
| Earning Date | 11-23-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.41 | 21.79 |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $3,129,100,000.00 | $655,353,000.00 |
| Revenue This Year | N/A | $10.80 |
| Revenue Next Year | $1.22 | $10.83 |
| P/E Ratio | $15.90 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $30.22 | $9.82 |
| 52 Week High | $47.36 | $21.45 |
| Indicator | CENT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 74.43 | 44.87 |
| Support Level | $42.52 | $13.33 |
| Resistance Level | $45.52 | $15.22 |
| Average True Range (ATR) | 1.30 | 0.64 |
| MACD | 0.52 | 0.07 |
| Stochastic Oscillator | 69.95 | 39.43 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.